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trophin protein. Two groups recently published data, a single-dose in-
travascular delivery of rAAV2/8-Spc512-μDys (Le Guiner et al., 2015)
and AAV-9 reporter or micro-dystrophin (μDys) vector at doses of
1.92–6.24 × 1014 viral genome particles/kg (Yue et al., 2015) in Golden
Retriever Muscular Dystrophy Dogs, the canine model of DMD. Overall,
the improvement of multiple muscle parameters was observed with no1. Identifying New Targets in Duchenne Muscular Dystrophy (DMD)
precipice in bridging the gap between late pre-clinical and early clinical
work on AAV gene-therapy, a few very important safety concerns asso-Increasing our understanding of the pathophysiologicalmechanisms
that manifest in DMD patients offers the opportunity to identify new
pharmacological targets. Dominic Wells and Thomas Voit, University
of London, provided insights into the most promising drug targets
currently under investigation to treat DMD. Increasing muscle mass
by inhibiting myostatin, has produced promising results with Pﬁzer's,
PF-06252616 in phase II and Bristol Myers Squibb, BMS-986089, in
early development. Decreasing muscle inﬂammation and ﬁbrosis has
been achieved by inhibiting the protein complex NFκB, and multiple
compounds are being tested in clinical trials. Improving mitochondrial
function is another strategy and stimulating PGC1a, which regulates
genes involved in energy metabolism, has shown therapeutic promise.
Progress is also being made in repurposing existing drugs. Tadalaﬁl
(also used to treat erectile dysfunction), is in phase III studies and in-
creases blood ﬂow to cardiac and skeletal muscle, while Simvastatin
(a lipid lowering drug), has been shown to effectively reverse dystrophic
pathology in preclinical trials (Whitehead et al., 2015). Identiﬁcation
of new druggable targets offers additional options to the healthcare
community and renewed hope for those living with this progressive
condition.2. Gene Therapy to Restore Dystrophin
Gene therapy applications to restore dystrophin expression iswidely
considered one of the most promising approaches for the treatment of
DMD. Recombinant adeno-associated virus vectors (rAAV) have been
well characterized over the past few years to deliver the functional dys-
trophin gene, as they are very efﬁcient in the transduction of skeletal
and cardiac muscle. However, full-length dystrophin cDNA exceeds
the packaging capacity for a single rAAV gene-delivery cassette. There-
fore, truncated versions, namely microdystophins, have been designedpen access article under the CC BY-Nreported severe adverse events. Whilst the DMD community are at a
ciatedwith route of delivery, immunogenicity of vectors and transgenes
remain to be addressed.
3. Gene Editing to Correct Dystrophin Mutations That Cause DMD
Various genome editing technologies have attempted to restore ex-
pression of the dystrophin gene in cells carrying dystrophin mutations.
Principal Investigator, Charles Gersbach fromDukeUniversity, USA, pre-
sented data showing how his lab has applied the CRISPR/Cas9 gene
editing system to restore the dystrophin reading frame in DMD patient
myoblasts (Gersbach, n.d.). Using single or multiplexed guide RNAs
(sgRNAs), a variety of mutations could be corrected by introducing
small targeted deletions, or removal of whole or even multiple
exons. Dystrophin protein was restored in correctly-targeted cells
and could be detected when these cells were transplanted into
mice (Ousterout et al., 2015). Theoretically, this approach can
correct N60% of DMD mutations, offering an exciting therapeutic
avenue. Gersbach was clear to point out that despite cautious
optimism, the CRISPR/Cas9 system needs reﬁning to improve its
targeting efﬁciency and minimize off-target activity. However, if
these challenges can be addressed, gene editing might be the molec-
ular tool to enable treatment of individual DMD mutations by preci-
sion medicine.
4. Combination Therapy to Treat DMD
In the absence of dystrophin, many negative pathway cycles get
activated in an attempt to compensate for the lack of dystrophin.
Each of the downstream aspects of the pathology associated with
DMD is being investigated as separate drug targets. Leading experts
are starting to consider the potential of combination treatment, as
they feel it is likely that a few of these targets could have additive
beneﬁt (Wells). Corticosteroid use is often a baseline inclusion
criteria for most trials, but this has not been extensively tested inC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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from other therapeutic areas; depending on whether this has been
well-studied in the pediatric setting, may have a faster-track to the
clinic. There needs to be a clear strategic and collaborative approach
on what potential poly-therapy (Ricotti et al., 2015) would be syner-
gistic based on the patients' genotype and/or stage of the condition
with a complementary robust safety pharmacology package for any
potential combination.
5. Magnetic Resonance Imaging (MRI) in DMD Management
Magnetic resonance imaging (MRI) is sensitive to alterations inmus-
cle composition and structure and can quantify measures related to in-
ﬂammation and skeletal muscle fat; it is used to assess inﬂammation,
ﬁbrosis, and fatty inﬁltration of skeletal muscle. At a recent European
Neuromuscular Centre workshop, natural history data was presented
inwhich fatty tissue depositionwithin one year in the soleus and vastus
lateralismuscles were observed in all DMD age groups (5–12 years old),
but not in the unaffected controls (Ferlini et al., 2015). Other recent
groups have used this quantitative muscle composition (fat fraction)
to assess the effect of treatment and its potential reduction correlated
with functional outcome measures. An ongoing observational Imaging
DMD study (Clinical trials.gov website, n.d.), at ﬁve US sites is compar-
ing the muscles of ambulatory boys with Duchenne with muscles of
healthy children of the same age to monitor disease progression over
a ﬁve year period. Considering the advances made in MRI and MR
spectroscopy, keymulti-national experts feel that this could be strongly
considered as a future potential non-invasive prognostic and pharmaco-
dynamics biomarker (Fig. 1).Fig. 1. The Conference Dinner.6. Developing Better Outcome Measures in DMD
Progress in preclinical strategies to tackle DMD has underscored the
need to rethink outcome measures for gauging therapeutic response in
clinical trials. Historically, clinical outcome measures comprised assess-
ment of walking skills, such as the 6-minute walk test and the North
Star Ambulatory Assessment.Whilst reliable, these tests are only applica-
ble to ambulatory boys, thereby precluding the involvement of non-
ambulatoryDMDpatients in clinical trials. AnnemiekeAartsma-Rus, coor-
dinator of the EU-funded TREAT-NMD network (TREAT-NMD website,
n.d.), spoke passionately about international efforts from patients, clini-
cians, physiotherapists, scientists, advocacy groups and industrial part-
ners to devise a roadmap to improve clinical outcome measures,
making them applicable to all DMDpatients. One strategy, is the develop-
ment of functional tests that measure the progressive decline in upper
limb movement that deteriorates in a proximal-distal direction, during
the course of the disease. The introduction of MyoTools (to measure
hand strength) and MRI modalities (to non-invasively measure disease
characteristics) can complement assessment, enabling treatment
response to be quantiﬁed. The hope is that tailoring the most accurate
clinical outcome measures for a speciﬁc clinical trial cohort will aid ther-
apeutic assessment and facilitate regulatory approval of themost promis-
ing candidates.
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